nach oben

Erschienen in:

01.12.2024 | Invited Review

Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review

verfasst von: Joao G. Porto, Renil Titus, Feres Camargo, Ansh Bhatia, Nehizena Ahie, Ruben Blachman-Braun, Ankur Malpani, Diana M. Lopategui, Thomas R. W. Herrmann, Robert Marcovich, Hemendra N. Shah

Erschienen in: World Journal of Urology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Past decade has seen a renewed interest in minimally invasive surgical techniques (MISTs) for management of enlarged prostate. This narrative review aims to explore newer MIST for benign prostatic hyperplasia (BPH) which are not yet integrated into established societal guidelines.

Methods

We conducted a literature search across PubMed, Google Scholar, and FDA ClinicalTrials.gov databases on June 1st, 2023, to identify studies published within the past decade exploring various MISTs for BPH. Additionally, we gathered insights from abstracts presented in meetings of professional associations and corporate websites. We broadly classified these procedures into three distinct categories: energy-based, balloon dilation, and implant/stent treatments. We collected detail information about the device, procedure details, its inclusion and exclusion criteria, and outcome.

Results

Our review reveals that newer energy-based MISTs include Transperineal Laser Ablation, Transurethral Ultrasound Ablation, and High-Intensity Focused Ultrasound. In the sphere of balloon dilation, Transurethral Columnar Balloon Dilation and the Optilume BPH Catheter System were gaining momentum. The noteworthy implants/stents that are on horizon include Butterfly Prostatic Retraction Device, Urocross Expander System, Zenflow Spring System, and ProVee Urethral Expander System.

Conclusion

The exploration of various MISTs reflects ongoing efforts to enhance patient care and address limitations of existing treatments. This review provides a bird-eye view and valuable insights for urologists and researchers seeking to navigate the dynamic landscape of MISTs in the quest for effective and minimally invasive solutions for enlarged prostates.

Strebel RT, Kaplan SA (2021) The state of TURP through a historical lens. World J Urol 39(7):2255–2262. https://doi.org/10.1007/s00345-021-03607-7CrossRefPubMed

Lerner LB, McVary KT, Barry MJ et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE. J Urol 206(4):806–817CrossRefPubMed

Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, Rieken M, Sakalis V, Tutolo M, Guidelines Associates: Baboudjian M, Bhatt N, Creta M, Karavitakis M, Moris L, Guidelines Office: Schouten N (2023) EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guidelines Office, Arnhem

Kwun-Chung Cheng B, Kar-Kei Yuen S, Castellani D, et al (2022) Defining minimal invasive surgical therapy for benign prostatic obstruction surgery: perspectives from a global knowledge, attitudes, and practices survey. Asian J Urol. https://doi.org/10.1016/j.ajur.2022.02.011

Checcucci E, Veccia A, De Cillis S et al (2021) New ultra-minimally invasive surgical treatment for benign prostatic hyperplasia: a systematic review and analysis of comparative outcomes. Eur Urol Open Sci 33:28–41. https://doi.org/10.1016/j.euros.2021.08.009CrossRefPubMedPubMedCentral

Elterman DS, Zorn KC, Chughtai B, Bhojani N (2021) Is it time to offer true minimally invasive treatments (TMIST) for BPH?—A review of office-based therapies and introduction of a new technology category. Can J Urol 28(2):10580–10583PubMed

Kuo HC (1998) Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia. Urol Int 60(2):85–91. https://doi.org/10.1159/000030217CrossRefPubMed

McVary KT, Gittelman MC, Goldberg KA et al (2021) Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 206(3):715–724. https://doi.org/10.1097/JU.0000000000001778CrossRefPubMed

Elterman D, Bhojani N, Vannabouathong C et al (2022) Large, multi-center, prospective registry of Rezūm water vapor therapy for benign prostatic hyperplasia. Urology 165:261–267. https://doi.org/10.1016/j.urology.2022.02.001CrossRefPubMed

10.

Patelli G, Ranieri A, Paganelli A et al (2017) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Intervent Radiol 40(9):1440–1446. https://doi.org/10.1007/s00270-017-1662-9CrossRefPubMed

11.

510(k) Premarket Notification Database—ECHOLASER X4. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=k181510

12.

Van Riel LAMJG, Van Kollenburg RAA, Vis AN et al (2022) Safety and feasibility of soractelite transperineal focal laser ablation for prostate cancer and short-term quality of life analysis from a multicenter pilot study. Eur Urol Open Sci 39:48–54. https://doi.org/10.1016/j.euros.2022.02.012CrossRefPubMedPubMedCentral

13.

Tafuri A, Panunzio A, De Carlo F, et al (2023) Transperineal laser ablation for benign prostatic enlargement: a systematic review and pooled analysis of pilot studies. JCM 12(5):1860. https://doi.org/10.3390/jcm12051860

14.

De Rienzo G, Lorusso A, Minafra P et al (2021) Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol 80(1):95–103. https://doi.org/10.1016/j.eururo.2020.08.018CrossRefPubMed

15.

Manenti G, Perretta T, Calcagni A et al (2021) 3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia. Eur Radiol Exp 5(1):41. https://doi.org/10.1186/s41747-021-00239-9CrossRefPubMedPubMedCentral

16.

Cai HJ, Fang JH, Kong FL et al (2022) Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy. Acta Radiol 63(4):553–558. https://doi.org/10.1177/02841851211003289CrossRefPubMed

17.

Sessa F, Polverino P, Siena G, et al (2023) Transperineal laser ablation of the prostate (TPLA) for lower urinary tract symptoms due to benign prostatic obstruction. JCM 12(3):793. https://doi.org/10.3390/jcm12030793

18.

van Kollenburg RAA, van Riel LAMJG, Bloemen PR et al (2020) Transperineal laser ablation treatment for lower urinary tract symptoms due to benign prostatic obstruction: protocol for a prospective in vivo pilot study. JMIR Res Protoc 9(1):e15687. https://doi.org/10.2196/15687

19.

Bertolo R, Iacovelli V, Cipriani C et al (2023) Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial. BJU Int 132(1):100–108. https://doi.org/10.1111/bju.16008CrossRefPubMed

20.

Cai H, Zhu C, Fang J (2023) Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: two similar short-term efficacies. Acta Radiol 64(5):2033–2039. https://doi.org/10.1177/02841851221140214CrossRefPubMed

21.

Zhang W, Zhang W, Guo Q et al (2021) The design and rationale of a multicentre randomised controlled trial comparing transperineal percutaneous laser ablation with transurethral resection of the prostate for treating benign prostatic hyperplasia. Front Surg 18(8):755957. https://doi.org/10.3389/fsurg.2021.755957CrossRef

22.

Klotz L, Pavlovich CP, Chin J et al (2021) Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol 205(3):769–779. https://doi.org/10.1097/JU.0000000000001362CrossRefPubMed

23.

Viitala A, Anttinen M, Wright C et al (2022) Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. BJU Int 129(2):208–216. https://doi.org/10.1111/bju.15523CrossRefPubMed

24.

Elterman D, Li W, Hatiboglu G, et al (2021) Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation for localized prostate cancer: subgroup analyses in patients with concurrent cancer and benign prostatic hyperplasia. J Endourol 35(4):497–505. https://doi.org/10.1089/end.2020.0511

25.

510(k) Premarket Notification Database—TULSA-PRO^® system. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K191200

26.

Rabinowitz MJ, Haney NM, Myers AA, et al (2023). Urinary outcomes after magnetic resonance imaging-guided whole-gland transurethral ultrasound ablation for prostate cancer: comparison of suprapubic tube to indwelling urethral catheter. J Endourol 37(1):1–7. https://doi.org/10.1089/end.2022.0214

27.

Bihrle R, Foster RS, Sanghvi NT et al (1994) High-intensity focused ultrasound in the treatment of prostatic tissue. Urology 43:21–26. https://doi.org/10.1016/0090-4295(94)90214-3CrossRefPubMed

28.

Madersbacher S, Schatzl G, Djavan B et al (2000) Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 37(6):687–694. https://doi.org/10.1159/000020219CrossRefPubMed

29.

Nahar B, Bhat A, Reis IM et al (2020) Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer. J Urol 204(3):483–489. https://doi.org/10.1097/JU.0000000000001015CrossRefPubMed

30.

Abreu AL, Peretsman S, Iwata A et al (2020) High intensity focused ultrasound hemigland ablation for prostate cancer: initial outcomes of a United States series. J Urol 204(4):741–747. https://doi.org/10.1097/JU.0000000000001126CrossRefPubMed

31.

National Library of Medicine (US) (2021) Evaluation of the safety of the treatment of benign prostatic hyperplasia by high intensity focused ultrasound [ClinicalTrials.gov identifier:NCT04853914]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT04853914

32.

Vale JA, Miller PD, Kirby RS (1993) Balloon dilatation of the prostate—should it have a place in the urologist’s armamentarium? J R Soc Med 86(2):83–86PubMedPubMedCentral

33.

Olweny EO, Jow SL, Jow WW (2022) Prolieve transurethral thermodilatation for treatment of symptomatic benign prostatic hyperplasia: 5-year results from a prospective multicenter trial. J Endourol 36(1):117–23. https://doi.org/10.1089/end.2021.0240

34.

Huang W, Huang Z, Xiao G, Qin X (2016) Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: a single-center experience of 565 consecutive patients. Medicine 95(40):e4657. https://doi.org/10.1097/MD.0000000000004657CrossRefPubMedPubMedCentral

35.

Zhou G, He J, Huang G, et al (2022) Efficacy and safety of transurethral columnar balloon dilation of the prostate for the treatment of benign prostatic hyperplasia: a multicenter trial. Computat Math Methods Med. https://doi.org/10.1155/2022/7881247

36.

Huang W, Guo Y, Xiao G, Qin X (2015) Treatment of benign prostatic hyperplasia using transurethral split of the prostate with a columnar balloon catheter. J Endourol 29(3):344–350. https://doi.org/10.1089/end.2014.0207CrossRefPubMed

37.

Zhang DP, Pan ZB, Zhang HT (2022) Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate. WJCC 10(20):6794–802. https://doi.org/10.12998/wjcc.v10.i20.6794

38.

Zhang M, Jia J, Meng Q, Wang D (2022) Clinical application of directional dilation in transurethral columnar balloon dilation of the prostate. Pak J Med Sci. https://doi.org/10.12669/pjms.38.6.5235

39.

Fang D, Yang Y, Li H et al (2022) A retrospective multi-center study of the clinical effects of transurethral columnar balloon dilation of the prostate in the treatment of elderly patients with benign prostatic hyperplasia. Arch Esp Urol 75(10):844. https://doi.org/10.56434/j.arch.esp.urol.20227510.122CrossRefPubMed

40.

Wang B, Zhang S, Sun C et al (2020) Comparison between a transurethral prostate split and transurethral prostate resection for benign prostatic hyperplasia treatment in a small prostate volume: a prospective controlled study. Ann Transl Med 8(16):1016–1016. https://doi.org/10.21037/atm-20-5462CrossRefPubMedPubMedCentral

41.

Elterman DS, Gao B, Zorn KC et al (2023) How I Do It: Optilume BPH catheter system. Can J Urol 30(3):11568–11573PubMed

42.

Kaplan SA, Pichardo M, Rijo E et al (2021) One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 24(4):1073–1079. https://doi.org/10.1038/s41391-021-00362-zCrossRefPubMedPubMedCentral

43.

Pichardo M, Rijo E, Espino G et al (2023) Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol 41(8):2209–2215. https://doi.org/10.1007/s00345-023-04473-1CrossRefPubMed

44.

Kaplan SA, Moss J, Freedman S et al (2023) The PINNACLE Study: a double-blind, randomized, sham-controlled study evaluating the optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 210(3):500–509. https://doi.org/10.1097/JU.0000000000003568CrossRefPubMed

45.

(2022) FDA approves the Optilume^® urethral drug coated balloon for the treatment of urethral strictures. BJU Int 129(3):305–305. https://doi.org/10.1111/bju.15716

46.

Virasoro R, DeLong J, Mann R, et al (2020) A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study. CUAJ. https://cuaj.ca/index.php/journal/article/view/6323

47.

Elliott SP, Coutinho K, Robertson KJ et al (2022) One-year results for the ROBUST III randomized controlled trial evaluating the Optilume^® drug-coated balloon for anterior urethral strictures. J Urol 207(4):866–875. https://doi.org/10.1097/JU.0000000000002346CrossRefPubMed

48.

Armitage JN, Cathcart PJ, Rashidian A et al (2007) Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 177(5):1619–1624. https://doi.org/10.1016/j.juro.2007.01.005CrossRefPubMed

49.

Armitage JN, Rashidian A, Cathcart PJ, et al (2006). The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int 98(4):806–10. https://doi.org/10.1111/j.1464-410X.2006.06399.x

50.

Peyton CC, Badlani GH (2015) The management of prostatic obstruction with urethral stents. Can J Urol 22(Suppl 1):75–81PubMed

51.

Porto JG, Arbelaez MCS, Blachman-Braun R et al (2023) Complications associated with minimally invasive surgical therapies (MIST) for surgical management of benign prostatic hyperplasia: a Manufacturer and User Facility Device Experience (MAUDE) database review. World J Urol. https://doi.org/10.1007/s00345-023-04440-wCrossRefPubMed

52.

Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH)—Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-and-clinical-investigation-devices-used-treatment-benign-prostatic-hyperplasia-bph

53.

Roehrborn CG, Chin PT, Woo HH (2022) The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis 25(1):79–85. https://doi.org/10.1038/s41391-021-00434-0CrossRefPubMed

54.

Elterman D, Gao B, Zorn KC et al (2021) How I Do It: temporarily implanted nitinol device (iTind). Can J Urol 28(4):10788–10793PubMed

55.

Katz R, Ahmed MSA, Safadi A et al (2023) The butterfly: a novel minimally invasive transurethral retraction device for benign hypertrophy of the prostate. Urol Int 107(4):406–412. https://doi.org/10.1159/000528415CrossRefPubMed

56.

Katz R, Sze C, Punyala A, et al (2023) Characterization of the histological response to the Butterfly Prostatic Retraction Device in patients with benign prostatic hyperplasia. World J Urol 41(4):1141–1146. https://doi.org/10.1007/s00345-023-04319-w

57.

National Library of Medicine (US) (2019) Pilot study to assess the safety and efficacy of butterfly medical prostatic retraction device in BPH patients [ClinicalTrials.gov identifier: NCT03912558]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03912558

58.

Sountoulides P, Karatzas A, Gravas S (2019) Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. Ther Adv Urol 11:175628721982897. https://doi.org/10.1177/1756287219828971CrossRef

59.

Chughtai B, Punyala A, Lata SS et al (2022) Characterization of a novel implant intended to expand and reshape the prostatic urethra for the treatment of benign prostatic hyperplasia: a pre-clinical feasibility study in the canine model. Urology 159:167–175. https://doi.org/10.1016/j.urology.2021.10.015CrossRefPubMed

60.

Woo HH, Huang CP, Huang WJ et al (2022) The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Prostate Cancer Prostatic Dis 25(3):576–582. https://doi.org/10.1038/s41391-022-00548-zCrossRefPubMedPubMedCentral

61.

National Library of Medicine (US) (2018) Safety and feasibility of the XFLO expander system (Mercury) (EXPANDER-1) [ClinicalTrials.gov identifier: NCT03758222]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03758222

62.

National Library of Medicine (US). (2022). The expander-2 trial: a randomized study to evaluate the safety and efficacy of the Urocross(TM) expander system and retrieval sheath [ClinicalTrials.gov identifier: NCT05400980]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT05400980

63.

Vjaters E, Nitsan D, Mullerad M (2020) First-in-man safety and efficacy of the ClearRing implant for the treatment of benign prostatic hyperplasia. Eur Urol Focus 6(1):131–136. https://doi.org/10.1016/j.euf.2018.09.013CrossRefPubMed

64.

Feld Y, Golan S, Leibovitch I (2018) Assessing the safety and efficacy of the ClearRing™ implant for the treatment of benign prostatic hyperplasia in a canine model. Curr Urol 11(4):206–211. https://doi.org/10.1159/000447220CrossRefPubMedPubMedCentral

65.

National Library of Medicine (US) (2016) The Zenflow spring system feasibility and safety study (ZEST) [ClinicalTrials.gov identifier: NCT02786290]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/record/NCT02786290

66.

Gao B, Lu S, Bhojani N et al (2021) Office-based procedures for BPH. Curr Urol Rep 22(12):63. https://doi.org/10.1007/s11934-021-01081-7CrossRefPubMed

67.

National Library of Medicine (US) (2018) The Zenflow spring system safety, performance and effectiveness study (ZEST2) [ClinicalTrials.gov identifier: NCT03595735]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03595735?intr=zenflow&viewType=Table&rank=3&tab=table

68.

National Library of Medicine (US) (2018) The Zenflow spring system EU safety and performance study (ZEST EU) [ClinicalTrials.gov identifier: NCT03577236]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03577236?intr=zenflow&viewType=Table&rank=1&tab=table

69.

National Library of Medicine (US) (2020) The Zenflow spring system safety and performance study (ZEST CAN) [ClinicalTrials.gov identifier: NCT04309695]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04309695?intr=zenflow&viewType=Table&rank=2&tab=table

70.

National Library of Medicine (US) (2021) Safety and effectiveness study of the Zenflow spring system (BREEZE) [ClinicalTrials.gov identifier: NCT04987138]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04987138?intr=zenflow&viewType=Table&rank=5&tab=table

71.

National Library of Medicine (US) (2019) The ProVerum first in man PROVE study [ClinicalTrials.gov identifier: NCT03972371]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03972371

72.

National Library of Medicine (US) (2021) ProVee Urethral Expander system IDE Study (ProVIDE) (ProVIDE) [ClinicalTrials.gov identifier: NCT05186740]. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT05186740

73.

Lynch TH, Lonergan PE, Anderson P (2023) PD41–04 first in man clinical data through 24-months of a novel, minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 209(Suppl 4). https://doi.org/10.1097/JU.0000000000003346.04

74.

Speakman MJ, Cornu JN, Gacci M et al (2019) What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction? Eur Urol Focus 5(3):351–356. https://doi.org/10.1016/j.euf.2019.05.014CrossRefPubMed

75.

Marra G, Sturch P, Oderda M et al (2016) Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men’s ejaculatory function: time for a bespoke approach? Int J Urol 23(1):22–35. https://doi.org/10.1111/iju.12866CrossRefPubMed

76.

Malde S, Umbach R, Wheeler JR et al (2021) A systematic review of patients’ values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol 79(6):796–809. https://doi.org/10.1016/j.eururo.2020.12.019CrossRefPubMed

77.

Pratsinis M, Müllhaupt G, Güsewell S, et al (2023) Comparison of traditional outcome measures and self-assessed goal achievement in patients treated surgically for benign prostatic hyperplasia. World J Urol 41(4):1125–31. https://doi.org/10.1007/s00345-023-04317-y

78.

Porto J, Suarez Arbelaez MC, Zarli M, et al (2023) Exploring the legal implications of benign prostatic hyperplasia surgeries in the United States: a comprehensive analysis of two decades of lawsuits. Cureus 15(5):e39335. https://doi.org/10.7759/cureus.39335

79.

Ganem S, Ambinder D, Kennedy A, Wong NC (2022) A 40-year litigation review of transurethral surgeries for benign prostatic hyperplasia. Urology 168:165–168. https://doi.org/10.1016/j.urology.2022.06.013CrossRefPubMed

80.

Elterman D, Matsumoto ED, Zorn KC (2023) PD41–02 12-month outcomes from the first north american study of the zenflow spring system for the treatment of benign prostatic hyperplasia (BPH). J Urol 209(Suppl 4). https://doi.org/10.1097/JU.0000000000003346.02

81.

Chin P, Gomez Guerra LS, Gilling P, et al (2021) MP09–03 evolution of the zenflow spring system: a novel nitinol implant for benign prostatic hyperplasia (BPH). J Urol 206(Suppl 3). https://doi.org/10.1097/JU.0000000000001982.03

82.

Gilling P, Brennan J, Chin P, et al (2021) PD23–06 12-month interim results of the multicenter, prospective, single-arm study with the zenflow spring system: a novel minimally-invasive treatment for luts associated with BPH. J Urol 206(Suppl 3). https://doi.org/10.1097/JU.0000000000002016.06

83.

Elterman DS, Coutinho K, Hagedorn JC (2020) How I Do It: The Optilume drug-coated balloon for urethral strictures. Can J Urol 27(4):10322–10328PubMed

Titel: Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review
verfasst von: Joao G. Porto
Renil Titus
Feres Camargo
Ansh Bhatia
Nehizena Ahie
Ruben Blachman-Braun
Ankur Malpani
Diana M. Lopategui
Thomas R. W. Herrmann
Robert Marcovich
Hemendra N. Shah
Publikationsdatum: 01.12.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 1/2024
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04747-8

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review